Last Update 03 Apr 26

CCRN: Margin Execution And Travel Nurse Demand Will Drive Bullish Thesis

Analysts have nudged their price targets for Cross Country Healthcare higher, with moves such as UBS lifting its target to $10 from $9 and Benchmark setting a $14 target. They cited improving travel nurse demand, confidence in a 4% to 5% adjusted EBITDA margin target by the end of 2026, and a clearer path toward higher margin segments and operating leverage.

Analyst Commentary

Recent research on Cross Country Healthcare gives you a clearer view of how the market is thinking about the stock, especially around its margin goals, demand for travel nurses, and the mix of business segments.

Bullish Takeaways

Bullish analysts point to improving demand for travel nurses as a key support for revenue stability and potential volume growth in the core staffing business.
The 4% to 5% adjusted EBITDA margin target by the end of 2026 is seen as credible, which, if met, could support stronger earnings power relative to the current business mix.
There is a clear focus on higher margin segments and operating leverage, which bullish analysts see as important drivers for lifting profitability without relying solely on higher bill rates.
Recent price target moves into the US$10 to US$14 range reflect a view that the current valuation leaves room for better execution on margins and segment mix.

Bearish Takeaways

Bearish analysts keep a neutral stance, signaling that while the margin plan is in place, execution risk around hitting the 4% to 5% adjusted EBITDA margin target remains a concern.
Some research frames the outlook as improving after what is described as a distracting year in 2025, which implies recent volatility in operations or performance that investors should weigh.
The travel nurse recovery is still a key assumption, and more cautious analysts highlight the risk that demand trends may not stay aligned with current expectations.
With at least one neutral rating maintained even after a higher price target, there is a view that recent positives may already be partly reflected in the stock, which may limit upside if execution falls short.

What's in the News

Cross Country Healthcare, Inc. (NasdaqGS: CCRN) was dropped from the S&P Health Care Services Select Industry Index, removing the stock from that benchmark group (Index Constituent Drops).
Management highlighted that the company is looking for acquisitions, with a focus on complementary deals that fit its existing customer footprint, technology platform, home-based staffing division, and locum tenens business, while also considering continued share repurchases as part of its capital allocation approach (Seeking Acquisitions/Investments).
From October 1, 2025 to December 31, 2025, the company repurchased 803,175 shares for US$6.51m, and in total has repurchased 6,433,235 shares for US$124.62m under the buyback announced on August 16, 2022 (Buyback Tranche Update).
For the first quarter of 2026, Cross Country Healthcare expects revenue to be in the range of US$235m to US$240m, providing a reference point for near-term sales expectations (Corporate Guidance).

Valuation Changes

Fair Value: The $11.67 estimate is unchanged, indicating no shift in the core valuation output used here.
Discount Rate: The 6.98% input remains effectively the same, so the required return assumption has not moved.
Revenue Growth: The 73.15% very large model input is essentially flat, showing no material adjustment to the long run top line growth assumption.
Net Profit Margin: The 100.22% very large margin assumption is effectively unchanged, so profitability expectations in the model are stable.
Future P/E: The 39.68x forward P/E input is steady, pointing to no revision in the valuation multiple applied to future earnings in this framework.

0 views

Key Takeaways

Increased demand and strategic investments in Travel Nursing and Physician Staffing segments drive significant revenue and growth potential.
Expansion of home care and technology integrations enhances margins and client retention, supporting long-term financial stability and growth.
Cross Country Healthcare faces significant revenue and margin pressure due to competitive compensation, market bill rate discrepancies, and delayed new deal revenues, impacting future profitability.

Catalysts

About Cross Country Healthcare

Provides talent management and other consultative services for healthcare clients in the United States.What are the underlying business or industry changes driving this perspective?

Cross Country Healthcare has seen an approximately 20% increase in orders in the Travel Nursing & Allied segment for the fourth quarter, indicating a potential inflection point and future volume growth, which may positively impact revenue.
The home care staffing segment is projected to grow in the mid-teens year-over-year in the fourth quarter and continues to expand its PACE programs nationwide, boosting revenue growth and potentially improving net margins due to a higher margin profile.
The Physician Staffing segment is experiencing strong demand, with expected low to mid-single-digit sequential revenue growth in the fourth quarter, facilitated by improved operating leverage and cost management, which should enhance both revenue and contribution income.
The company’s technology platform, Intellify, is expected to fully integrate all clients by the end of the year, which is anticipated to increase spend under management and drive revenue growth through improved margin contracts and client retention.
Cross Country Healthcare is focusing on capital allocation for potential M&A opportunities and strategic investments in technology, which could further expand the portfolio and enhance earnings growth while maintaining a strong balance sheet with no outstanding debt.

Cross Country Healthcare Earnings and Revenue Growth

Cross Country Healthcare Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cross Country Healthcare's revenue will remain fairly flat over the next 3 years.
Analysts assume that profit margins will increase from -9.0% today to 1.0% in 3 years time.
Analysts expect earnings to reach $10.8 million (and earnings per share of $0.33) by about April 2029, up from -$94.9 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 41.0x on those 2029 earnings, up from -3.1x today. This future PE is greater than the current PE for the US Healthcare industry at 22.0x.
Analysts expect the number of shares outstanding to decline by 1.42% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Cross Country Healthcare faces gross margin pressures due to competitive compensation packages in the Travel Nursing and Allied markets, impacting its profitability and ability to normalize margins in the near term. This could affect net margins negatively.
The company's revenue in the third quarter of 2024 was down 7% sequentially and 29% year-over-year, primarily due to expected declines in Travel Nursing and Allied. This potential continuing decline poses a risk to overall revenue growth.
Over 50% of job orders are not at market bill rates, which could limit Cross Country Healthcare's ability to increase production and fill assignments, potentially impacting revenue growth and overall earnings.
Despite expectations of growth, the Physician Staffing segment might face capacity limits and increased costs if additional resources are needed to sustain growth, impacting net margins.
While the company is focusing on M&A opportunities, the longer decision-making cycles at hospitals for MSP and VMS contracts could delay potential revenue from new deals, affecting revenue projections and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $11.67 for Cross Country Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $15.0, and the most bearish reporting a price target of just $10.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $10.8 million, and it would be trading on a PE ratio of 41.0x, assuming you use a discount rate of 7.0%.
Given the current share price of $9.18, the analyst price target of $11.67 is 21.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cross Country Healthcare?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Full Client Integration With Intellify Will Improve Client Retention